Review



dexcom g4  (Dexcom Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Dexcom Inc dexcom g4
    Dexcom G4, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dexcom+g4/dexcom+g4/pmc13268403-113-37-37
    Average 86 stars, based on 1 article reviews
    dexcom g4 - by Bioz Stars, 2026-09
    86/100 stars

    Images

    Related Articles

    Software:

    Article Title: Performance of three simultaneously used rtCGM systems around a physically active weekend camp in adults with type 1 diabetes: A prospective lab and real‐world study
    Article Snippet: However, sensor performance remains a critical factor, especially under physiologically variable conditions such as exercise., As rtCGM systems assess glucose levels in the interstitial fluid, there is a physiological delay before the glucose diffuses into the blood vessels or from the blood vessels into the interstitial space., , Therefore, blood glucose concentrations and interstitial fluid concentrations measured, for example, during moderate‐intensity exercise, face a lag time of 12 ± 11 min, as shown in a study by Zaharieva et al. that investigated the lag time during exercise using the Dexcom G4 and G5.

    Article Title: A Review of the Fear of Hypoglycemia Literature in Children and Adolescents with Type 1 Diabetes and their Caregivers
    Article Snippet: Ng et al. (2019) (15) United Kingdom , Caregivers n = 16 Youth n = 11 , Med = 13.5 yrs; 2–17 yrs , 12-mo longitudinal; within subjects , Dexcom ® G4 , PHFS M Behavior = 38.38 M Worry = 60.31 M Total = 98.69 CHFS M Behavior = 40.88 M Worry = 56.00 M Total = 97.38 , PHFS Follow-up scores M Behavior = 25.00*** M Worry = 41.69*** M Total = 66.69*** CHFS Follow-up scores M Behavior = 24.13** M Worry = 35.61** M Total = 59.75**.

    Article Title: Accuracy of continuous glucose monitoring in critically ill patients
    Article Snippet: Of the 103 patients, the Dexcom G4 was applied in 57 and Dexcom G6 in 46.

    Article Title: Evolution and Future of Glucose Monitoring: From Blood Glucose Meters to Continuous Systems and Their Projected Impact in the Middle East and North Africa (MENA) Region
    Article Snippet: Real-time CGM (rtCGM): Systems like the Dexcom G4 (Dexcom, San Diego, CA, USA) and Medtronic Guardian introduced real-time glucose display, and customizable alerts and alarms for hypoglycemia and hyperglycemia.

    Article Title: Prevalence, duration, and clinical implications of Continuous Glucose Monitor (CGM) measurement limit capping in type 1 diabetes
    Article Snippet: Our datasets primarily comprise Dexcom G4 and G6 systems rather than the newest CGM platforms such as Dexcom G7 or FreeStyle Libre 3.



    Similar Products

    dexcom g4  (Dexcom Inc)
    86
    Dexcom Inc dexcom g4
    Dexcom G4, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dexcom+g4/dexcom+g4/pmc13268403-113-37-37
    Average 86 stars, based on 1 article reviews
    dexcom g4 - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    dexcom g4 platinum  (Dexcom Inc)
    86
    Dexcom Inc dexcom g4 platinum
    Proposed amended reporting format for CGM sensor measurement limit capping, illustrated using two exemplar 14-day windows from the Aleppo 2017 Replace-BG trial (Dexcom <t>G4</t> Platinum) for the participant with the highest proportion of upper-limit capped readings (A-D) and the participant with the highest proportion of lower-limit capped readings (E-H). Panels A and E show the ambulatory glucose profile (AGP) with median glucose (red line) and shaded 25–75% and 10–90% interpercentile ranges. Grey shaded bands above and below the dashed device detection limit lines (400 and 40 mg/dL) indicate the glucose range that cannot be measured by the device. Panels B and F show glucose-range exposure as a stacked bar chart, with black segments at the top and bottom representing readings at or beyond the device detection limits, extending the standard display. Panels C and G summarise conventional window-level metrics alongside device-limit capping statistics (frequency and longest run duration), and panels D and H show the glucose frequency distribution with lower and upper capped bins shaded black. These display elements are proposed as optional additions to standard CGM reporting software, to be shown only when capping is present.
    Dexcom G4 Platinum, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dexcom+g4/dexcom+g4+platinum/med_rxiv__64898__2026__05__13__26353094-33-15-15
    Average 86 stars, based on 1 article reviews
    dexcom g4 platinum - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    dexcom g4 platinum sensor  (Dexcom Inc)
    86
    Dexcom Inc dexcom g4 platinum sensor
    Proposed amended reporting format for CGM sensor measurement limit capping, illustrated using two exemplar 14-day windows from the Aleppo 2017 Replace-BG trial (Dexcom <t>G4</t> Platinum) for the participant with the highest proportion of upper-limit capped readings (A-D) and the participant with the highest proportion of lower-limit capped readings (E-H). Panels A and E show the ambulatory glucose profile (AGP) with median glucose (red line) and shaded 25–75% and 10–90% interpercentile ranges. Grey shaded bands above and below the dashed device detection limit lines (400 and 40 mg/dL) indicate the glucose range that cannot be measured by the device. Panels B and F show glucose-range exposure as a stacked bar chart, with black segments at the top and bottom representing readings at or beyond the device detection limits, extending the standard display. Panels C and G summarise conventional window-level metrics alongside device-limit capping statistics (frequency and longest run duration), and panels D and H show the glucose frequency distribution with lower and upper capped bins shaded black. These display elements are proposed as optional additions to standard CGM reporting software, to be shown only when capping is present.
    Dexcom G4 Platinum Sensor, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dexcom+g4/dexcom+g4+platinum/med_rxiv__64898__2026__05__13__26353094-140-16-16
    Average 86 stars, based on 1 article reviews
    dexcom g4 platinum sensor - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    dexcom g4 dataset  (Dexcom Inc)
    86
    Dexcom Inc dexcom g4 dataset
    Proposed amended reporting format for CGM sensor measurement limit capping, illustrated using two exemplar 14-day windows from the Aleppo 2017 Replace-BG <t>trial</t> <t>(Dexcom</t> <t>G4</t> Platinum) for the participant with the highest proportion of upper-limit capped readings (A-D) and the participant with the highest proportion of lower-limit capped readings (E-H). Panels A and E show the ambulatory glucose profile (AGP) with median glucose (red line) and shaded 25–75% and 10–90% interpercentile ranges. Grey shaded bands above and below the dashed device detection limit lines (400 and 40 mg/dL) indicate the glucose range that cannot be measured by the device. Panels B and F show glucose-range exposure as a stacked bar chart, with black segments at the top and bottom representing readings at or beyond the device detection limits, extending the standard display. Panels C and G summarise conventional window-level metrics alongside device-limit capping statistics (frequency and longest run duration), and panels D and H show the glucose frequency distribution with lower and upper capped bins shaded black. These display elements are proposed as optional additions to standard CGM reporting software, to be shown only when capping is present.
    Dexcom G4 Dataset, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dexcom+g4/dexcom+g4/med_rxiv__64898__2026__05__13__26353094-81-9-9
    Average 86 stars, based on 1 article reviews
    dexcom g4 dataset - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    dexcom g4 cgm recordings  (Dexcom Inc)
    86
    Dexcom Inc dexcom g4 cgm recordings
    Proposed amended reporting format for CGM sensor measurement limit capping, illustrated using two exemplar 14-day windows from the Aleppo 2017 Replace-BG <t>trial</t> <t>(Dexcom</t> <t>G4</t> Platinum) for the participant with the highest proportion of upper-limit capped readings (A-D) and the participant with the highest proportion of lower-limit capped readings (E-H). Panels A and E show the ambulatory glucose profile (AGP) with median glucose (red line) and shaded 25–75% and 10–90% interpercentile ranges. Grey shaded bands above and below the dashed device detection limit lines (400 and 40 mg/dL) indicate the glucose range that cannot be measured by the device. Panels B and F show glucose-range exposure as a stacked bar chart, with black segments at the top and bottom representing readings at or beyond the device detection limits, extending the standard display. Panels C and G summarise conventional window-level metrics alongside device-limit capping statistics (frequency and longest run duration), and panels D and H show the glucose frequency distribution with lower and upper capped bins shaded black. These display elements are proposed as optional additions to standard CGM reporting software, to be shown only when capping is present.
    Dexcom G4 Cgm Recordings, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dexcom+g4/cgm+dexcom+g4/med_rxiv__64898__2026__04__22__26351476-35-3-3
    Average 86 stars, based on 1 article reviews
    dexcom g4 cgm recordings - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    dexcom g4 sensor  (Dexcom Inc)
    86
    Dexcom Inc dexcom g4 sensor
    Proposed amended reporting format for CGM sensor measurement limit capping, illustrated using two exemplar 14-day windows from the Aleppo 2017 Replace-BG <t>trial</t> <t>(Dexcom</t> <t>G4</t> Platinum) for the participant with the highest proportion of upper-limit capped readings (A-D) and the participant with the highest proportion of lower-limit capped readings (E-H). Panels A and E show the ambulatory glucose profile (AGP) with median glucose (red line) and shaded 25–75% and 10–90% interpercentile ranges. Grey shaded bands above and below the dashed device detection limit lines (400 and 40 mg/dL) indicate the glucose range that cannot be measured by the device. Panels B and F show glucose-range exposure as a stacked bar chart, with black segments at the top and bottom representing readings at or beyond the device detection limits, extending the standard display. Panels C and G summarise conventional window-level metrics alongside device-limit capping statistics (frequency and longest run duration), and panels D and H show the glucose frequency distribution with lower and upper capped bins shaded black. These display elements are proposed as optional additions to standard CGM reporting software, to be shown only when capping is present.
    Dexcom G4 Sensor, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dexcom+g4/dexcom+g4+sensor/pmc13065641-63-9-9
    Average 86 stars, based on 1 article reviews
    dexcom g4 sensor - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    ed continuous glucose monitors dexcom g4 dexcom g5 dexcom g6 enlite eversence freestyle libre freestyle libre 2 guardian sensor 3 guardian sensor 4  (Dexcom Inc)
    86
    Dexcom Inc ed continuous glucose monitors dexcom g4 dexcom g5 dexcom g6 enlite eversence freestyle libre freestyle libre 2 guardian sensor 3 guardian sensor 4
    Proposed amended reporting format for CGM sensor measurement limit capping, illustrated using two exemplar 14-day windows from the Aleppo 2017 Replace-BG <t>trial</t> <t>(Dexcom</t> <t>G4</t> Platinum) for the participant with the highest proportion of upper-limit capped readings (A-D) and the participant with the highest proportion of lower-limit capped readings (E-H). Panels A and E show the ambulatory glucose profile (AGP) with median glucose (red line) and shaded 25–75% and 10–90% interpercentile ranges. Grey shaded bands above and below the dashed device detection limit lines (400 and 40 mg/dL) indicate the glucose range that cannot be measured by the device. Panels B and F show glucose-range exposure as a stacked bar chart, with black segments at the top and bottom representing readings at or beyond the device detection limits, extending the standard display. Panels C and G summarise conventional window-level metrics alongside device-limit capping statistics (frequency and longest run duration), and panels D and H show the glucose frequency distribution with lower and upper capped bins shaded black. These display elements are proposed as optional additions to standard CGM reporting software, to be shown only when capping is present.
    Ed Continuous Glucose Monitors Dexcom G4 Dexcom G5 Dexcom G6 Enlite Eversence Freestyle Libre Freestyle Libre 2 Guardian Sensor 3 Guardian Sensor 4, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dexcom+g4/continuous+glucose+monitors/pm41936552-197-45-49
    Average 86 stars, based on 1 article reviews
    ed continuous glucose monitors dexcom g4 dexcom g5 dexcom g6 enlite eversence freestyle libre freestyle libre 2 guardian sensor 3 guardian sensor 4 - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    dexcom g4 cgm devices  (Dexcom Inc)
    86
    Dexcom Inc dexcom g4 cgm devices
    Proposed amended reporting format for CGM sensor measurement limit capping, illustrated using two exemplar 14-day windows from the Aleppo 2017 Replace-BG <t>trial</t> <t>(Dexcom</t> <t>G4</t> Platinum) for the participant with the highest proportion of upper-limit capped readings (A-D) and the participant with the highest proportion of lower-limit capped readings (E-H). Panels A and E show the ambulatory glucose profile (AGP) with median glucose (red line) and shaded 25–75% and 10–90% interpercentile ranges. Grey shaded bands above and below the dashed device detection limit lines (400 and 40 mg/dL) indicate the glucose range that cannot be measured by the device. Panels B and F show glucose-range exposure as a stacked bar chart, with black segments at the top and bottom representing readings at or beyond the device detection limits, extending the standard display. Panels C and G summarise conventional window-level metrics alongside device-limit capping statistics (frequency and longest run duration), and panels D and H show the glucose frequency distribution with lower and upper capped bins shaded black. These display elements are proposed as optional additions to standard CGM reporting software, to be shown only when capping is present.
    Dexcom G4 Cgm Devices, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dexcom+g4/cgm+dexcom+g4/pmc13033590-36-2-2
    Average 86 stars, based on 1 article reviews
    dexcom g4 cgm devices - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    Proposed amended reporting format for CGM sensor measurement limit capping, illustrated using two exemplar 14-day windows from the Aleppo 2017 Replace-BG trial (Dexcom G4 Platinum) for the participant with the highest proportion of upper-limit capped readings (A-D) and the participant with the highest proportion of lower-limit capped readings (E-H). Panels A and E show the ambulatory glucose profile (AGP) with median glucose (red line) and shaded 25–75% and 10–90% interpercentile ranges. Grey shaded bands above and below the dashed device detection limit lines (400 and 40 mg/dL) indicate the glucose range that cannot be measured by the device. Panels B and F show glucose-range exposure as a stacked bar chart, with black segments at the top and bottom representing readings at or beyond the device detection limits, extending the standard display. Panels C and G summarise conventional window-level metrics alongside device-limit capping statistics (frequency and longest run duration), and panels D and H show the glucose frequency distribution with lower and upper capped bins shaded black. These display elements are proposed as optional additions to standard CGM reporting software, to be shown only when capping is present.

    Journal: medRxiv

    Article Title: Prevalence, duration, and clinical implications of Continuous Glucose Monitor (CGM) measurement limit capping in type 1 diabetes

    doi: 10.64898/2026.05.13.26353094

    Figure Lengend Snippet: Proposed amended reporting format for CGM sensor measurement limit capping, illustrated using two exemplar 14-day windows from the Aleppo 2017 Replace-BG trial (Dexcom G4 Platinum) for the participant with the highest proportion of upper-limit capped readings (A-D) and the participant with the highest proportion of lower-limit capped readings (E-H). Panels A and E show the ambulatory glucose profile (AGP) with median glucose (red line) and shaded 25–75% and 10–90% interpercentile ranges. Grey shaded bands above and below the dashed device detection limit lines (400 and 40 mg/dL) indicate the glucose range that cannot be measured by the device. Panels B and F show glucose-range exposure as a stacked bar chart, with black segments at the top and bottom representing readings at or beyond the device detection limits, extending the standard display. Panels C and G summarise conventional window-level metrics alongside device-limit capping statistics (frequency and longest run duration), and panels D and H show the glucose frequency distribution with lower and upper capped bins shaded black. These display elements are proposed as optional additions to standard CGM reporting software, to be shown only when capping is present.

    Article Snippet: The Brown, Lynch, and Wadwa studies used the Dexcom G6 CGM, and Aleppo used the Dexcom G4 Platinum.

    Techniques: Software

    Proposed amended reporting format for CGM sensor measurement limit capping, illustrated using two exemplar 14-day windows from the Aleppo 2017 Replace-BG trial (Dexcom G4 Platinum) for the participant with the highest proportion of upper-limit capped readings (A-D) and the participant with the highest proportion of lower-limit capped readings (E-H). Panels A and E show the ambulatory glucose profile (AGP) with median glucose (red line) and shaded 25–75% and 10–90% interpercentile ranges. Grey shaded bands above and below the dashed device detection limit lines (400 and 40 mg/dL) indicate the glucose range that cannot be measured by the device. Panels B and F show glucose-range exposure as a stacked bar chart, with black segments at the top and bottom representing readings at or beyond the device detection limits, extending the standard display. Panels C and G summarise conventional window-level metrics alongside device-limit capping statistics (frequency and longest run duration), and panels D and H show the glucose frequency distribution with lower and upper capped bins shaded black. These display elements are proposed as optional additions to standard CGM reporting software, to be shown only when capping is present.

    Journal: medRxiv

    Article Title: Prevalence, duration, and clinical implications of Continuous Glucose Monitor (CGM) measurement limit capping in type 1 diabetes

    doi: 10.64898/2026.05.13.26353094

    Figure Lengend Snippet: Proposed amended reporting format for CGM sensor measurement limit capping, illustrated using two exemplar 14-day windows from the Aleppo 2017 Replace-BG trial (Dexcom G4 Platinum) for the participant with the highest proportion of upper-limit capped readings (A-D) and the participant with the highest proportion of lower-limit capped readings (E-H). Panels A and E show the ambulatory glucose profile (AGP) with median glucose (red line) and shaded 25–75% and 10–90% interpercentile ranges. Grey shaded bands above and below the dashed device detection limit lines (400 and 40 mg/dL) indicate the glucose range that cannot be measured by the device. Panels B and F show glucose-range exposure as a stacked bar chart, with black segments at the top and bottom representing readings at or beyond the device detection limits, extending the standard display. Panels C and G summarise conventional window-level metrics alongside device-limit capping statistics (frequency and longest run duration), and panels D and H show the glucose frequency distribution with lower and upper capped bins shaded black. These display elements are proposed as optional additions to standard CGM reporting software, to be shown only when capping is present.

    Article Snippet: Our BGM comparison is restricted to a single arm of a single trial using the older Dexcom G4 Platinum sensor (mean absolute relative difference (MARD) ∼14%), which has lower accuracy than the Dexcom G6 (MARD ∼9%) used in three of our four datasets.

    Techniques: Software

    Proposed amended reporting format for CGM sensor measurement limit capping, illustrated using two exemplar 14-day windows from the Aleppo 2017 Replace-BG trial (Dexcom G4 Platinum) for the participant with the highest proportion of upper-limit capped readings (A-D) and the participant with the highest proportion of lower-limit capped readings (E-H). Panels A and E show the ambulatory glucose profile (AGP) with median glucose (red line) and shaded 25–75% and 10–90% interpercentile ranges. Grey shaded bands above and below the dashed device detection limit lines (400 and 40 mg/dL) indicate the glucose range that cannot be measured by the device. Panels B and F show glucose-range exposure as a stacked bar chart, with black segments at the top and bottom representing readings at or beyond the device detection limits, extending the standard display. Panels C and G summarise conventional window-level metrics alongside device-limit capping statistics (frequency and longest run duration), and panels D and H show the glucose frequency distribution with lower and upper capped bins shaded black. These display elements are proposed as optional additions to standard CGM reporting software, to be shown only when capping is present.

    Journal: medRxiv

    Article Title: Prevalence, duration, and clinical implications of Continuous Glucose Monitor (CGM) measurement limit capping in type 1 diabetes

    doi: 10.64898/2026.05.13.26353094

    Figure Lengend Snippet: Proposed amended reporting format for CGM sensor measurement limit capping, illustrated using two exemplar 14-day windows from the Aleppo 2017 Replace-BG trial (Dexcom G4 Platinum) for the participant with the highest proportion of upper-limit capped readings (A-D) and the participant with the highest proportion of lower-limit capped readings (E-H). Panels A and E show the ambulatory glucose profile (AGP) with median glucose (red line) and shaded 25–75% and 10–90% interpercentile ranges. Grey shaded bands above and below the dashed device detection limit lines (400 and 40 mg/dL) indicate the glucose range that cannot be measured by the device. Panels B and F show glucose-range exposure as a stacked bar chart, with black segments at the top and bottom representing readings at or beyond the device detection limits, extending the standard display. Panels C and G summarise conventional window-level metrics alongside device-limit capping statistics (frequency and longest run duration), and panels D and H show the glucose frequency distribution with lower and upper capped bins shaded black. These display elements are proposed as optional additions to standard CGM reporting software, to be shown only when capping is present.

    Article Snippet: Upper-limit capping prevalence did not differ significantly between the Dexcom G4 dataset (Aleppo, n=226) and the three combined Dexcom G6 datasets (Brown, Lynch, Wadwa; n=722) for percentage of readings at the upper cap (median 0.116% vs 0.151%, p=0.091), total upper-cap time (388 vs 300 minutes, p=0.171), or number of upper-cap runs (7 vs 8, p=0.202) (Supplementary table S14).

    Techniques: Software